Relay Therapeutics Inc (NASDAQ: RLAY) — Perfil da empresa, notícias e dados financeiros
Relay Therapeutics leverages computational biology to discover new therapies targeting oncology and genetic disorders.

Relay Therapeutics Inc
Relay Therapeutics (NASDAQ:RLAY) is a company focused on leveraging advances in computational and structural biology to discover and develop new therapies. It operates at the forefront of precision medicine, with projects spanning from early discovery to clinical development, primarily targeting oncology and genetic disorders. Relay Therapeutics is passionate about deploying its proprietary technology to identify and develop molecules that can modulate protein functions in a dynamic manner, aiming to tackle diseases with high unmet medical needs. Its main objectives include advancing its current pipeline of potential treatments through clinical trials, expanding its research into new therapeutic areas, and continuously improving its drug discovery platform for better efficacy and patient outcomes. Relay Therapeutics is singularly listed on the NASDAQ under the ticker symbol RLAY, indicating its firm position in the biotechnology sector and commitment to innovation in drug discovery.
Resumo
Operações
Produtos e/ou serviços de Relay Therapeutics Inc
- Ripretinib, a tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors.
- FGFR2 programs, focusing on advanced and metastatic cancers with FGFR2 fusions or mutations.
- PI3Ka inhibitor projects, targeting solid tumors with specific genetic mutations.
- SH2-containing inositol-5'-phosphatase (SHIP2) inhibition program for metabolic disorders.
- Protein motion inhibitors, a novel class aiming at undruggable targets across various cancers.
- Machine learning platforms for drug discovery, enhancing the speed and efficacy of identifying therapeutic candidates.
equipe executiva do Relay Therapeutics Inc
- Sanjiv K. PatelCEO, President & Director
- Mark MurckoFounder & Independent Director
- Thomas CatinazzoChief Financial Officer
- Peter RahmerChief Corporate Development Officer
- Donald A. BergstromPresident of Research & Development
- Dorothee KernFounder
- David Elliot ShawFounder
- Matthew P. JacobsonFounder
- Jim WattersChief Scientific Officer
- Soo-Yeun LimSenior VP & General Counsel
Últimas notícias sobre a Relay Therapeutics Inc
Relay Therapeutics rallies on initial trial data for rare disease drug
United StatesRelay Therapeutics to advance Zovegalisib to Phase 3 breast cancer trial
United StatesRelay Therapeutics reports 11-month median PFS for Zovegalisib in breast cancer
United StatesRelay Therapeutics reports positive subset efficacy data for zovegalisib in combination with fulvestrant
United States
Principais indicadores financeiros
Resultados divulgados pela Relay Therapeutics Inc, em USD.
- Cap. de mercado
- 4,1 bi
- Receita (TTM)
- 10,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 15,4 mi | -302,7 mi | -276,5 mi | |
| 10 mi | -372,5 mi | -337,7 mi | |
| 25,5 mi | -373 mi | -342 mi | |
| 1,4 mi | -299,3 mi | -290,5 mi |